NRIX - Company ID 0001549595
The table below shows Nurix Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M | $17.82M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $316.90M | $221.63M | $189.15M | $184.50M | $116.43M | $66.49M |
| SG&A |
Nurix Therapeutics, Inc. reported annual revenue of $83.98M for fiscal year 2025. That is up 54.0% from $54.55M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $31.11M (FY 2019) to $83.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $52.74M |
| $45.94M |
| $42.90M |
| $38.00M |
| $31.20M |
| $16.31M |
| Operating income | -$285.67M | -$213.03M | -$155.06M | -$183.87M | -$117.89M | -$64.98M |
| Income tax | $760.00K | $270.00K | $0.00 | $0.00 | $131.00K | -$20.54M |
| Net income | -$264.46M | -$193.57M | -$143.95M | -$180.36M | -$117.19M | -$43.24M |
| EPS (diluted) | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | - |